Drugs Made In America Acquisition II (NASDAQ:DMII) Issues Quarterly Earnings Results

Posted by Brian Himes on Aug 15th, 2026

Drugs Made In America Acquisition II (NASDAQ:DMII – Get Free Report) announced its earnings results on Friday. The company reported $0.07 earnings per share for the quarter, FiscalAI reports.

Drugs Made In America Acquisition II Trading Down 0.0%

DMII traded down $0.01 during midday trading on Friday, reaching $10.12. 5,125 shares of the company’s stock traded hands, compared to its average volume of 114,100. Drugs Made In America Acquisition II has a 52 week low of $9.86 and a 52 week high of $10.20. The firm has a fifty day moving average of $10.10 and a two-hundred day moving average of $10.03.

Analysts Set New Price Targets

Several analysts have recently weighed in on DMII shares. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Read Our Latest Analysis on DMII

Institutional Trading of Drugs Made In America Acquisition II

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC purchased a new position in Drugs Made In America Acquisition II during the 4th quarter valued at $265,000. Virtu Financial LLC purchased a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter worth about $317,000. ABC Arbitrage SA purchased a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter worth about $396,000. Deltec Asset Management LLC bought a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter valued at about $495,000. Finally, Royal Bank of Canada bought a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter valued at about $655,000.

About Drugs Made In America Acquisition II

(Get Free Report)

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.